{'fraction_non_alphanumeric': 0.03581117742810635, 'fraction_numerical': 0.024416711882799782, 'mean_word_length': 5.2087542087542085, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
IDENTIFYING PATIENTS AT HIGH RISK OF MORTALITY AND READMISSION AFTER DECOMPENSATED HEART FAILURE: PROGNOSTIC SIGNIFICANCE OF 1-MONTH POSTDISCHARGE BNP

Background: In individuals with congestive heart failure, B-type natriuretic peptide (BNP) levels may indicate future cardiovascular complications. The majority of research has linked baseline B-type natriuretic peptide (BNP) levels to lengthy effects. The prognostic value of 1-month post-discharge BNP concentrations in acute heart failure is little understood.
Method: Patients who were hospitalized repeatedly for deteriorating heart failure were included. BNP levels were evaluated at admission, prior to discharge, and 15 days after discharge. For 6 months, patients were monitored for mortality and readmission to the hospital as endpoints.
Results: The heart failure study involved a total of 100 patients, with an average age of 60.7 ± 13.7 years. 80 patients (53%) experienced acute heart failure as a result of acute coronary syndrome, while the remaining 20 patients (45%) experienced sudden decompensation of chronic heart failure regardless of the underlying cause. The ejection fraction on average was 28.5 ± 8.8%. 13 people passed away while they were hospitalized. P value =0.002 indicates that BNP upon admission was a significant predictor of in-hospital death. Over the next one month, 5 incidents (2 fatalities and 3 re-hospitalizations) happened after release. Both the baseline and discharge BNP values (P values =0.02 and 0.002, respectively) were predictive of the 1-month outcome. 
Conclusion: BNP concentration is a helpful prognostic indicator that, in confirmed cases with heart failure, predicts death and rehospitalization at 1-month follow-up and aids in the identification of patients who require more extensive medication treatment and continuous follow-up.